Health Care & Life Sciences » Biotechnology | Kitov Pharmaceuticals Holdings Ltd.

Kitov Pharmaceuticals Holdings Ltd. ADR | Income Statement

Fiscal year is January-December. All values ILS Thousands.
2013
2014
2015
2016
2017
2018
Cost of Goods Sold (COGS) incl. D&A
-
-
3.90
7.70
14.40
25.20
Gross Income
-
-
3.90
7.70
14.40
3,570.10
SG&A Expense
4,223.10
15,957.90
15,805.10
27,566.20
36,455.30
37,592.10
EBIT
4,223.10
15,957.90
15,809.00
27,573.90
36,469.70
34,022
Unusual Expense
4,992.00
-
-
19,266.80
10,686.60
12,522.30
Non Operating Income/Expense
97.50
3,720.30
881.90
234.20
79.10
1,175.70
Interest Expense
173.30
-
-
-
93.50
32.40
Pretax Income
9,485.80
19,667.40
16,325.70
46,545.00
46,789.40
20,022
Consolidated Net Income
9,485.80
19,667.40
16,325.70
46,545.00
46,789.40
20,022
Net Income
9,485.80
19,667.40
16,325.70
46,545.00
44,142.10
18,695.40
Net Income After Extraordinaries
9,485.80
19,667.40
16,325.70
46,545.00
44,142.10
18,695.40
Net Income Available to Common
9,485.80
19,667.40
16,325.70
46,545.00
44,142.10
18,695.40
EPS (Basic)
43.31
4.40
0.85
0.42
0.22
1.32
Basic Shares Outstanding
219.00
4,482.00
19,250.30
115,114.90
189,139.00
14,205.30
EPS (Diluted)
43.31
4.39
0.85
0.40
0.23
1.32
Diluted Shares Outstanding
219.00
4,482.00
19,250.30
115,114.90
189,139.00
14,205.30
EBITDA
4,223.10
15,957.90
15,805.10
27,566.20
36,455.30
33,996.80
Non-Operating Interest Income
-
10.70
365.20
529.80
381.30
334.40
Minority Interest Expense
-
-
-
-
2,647.40
1,326.70

About Kitov Pharmaceuticals Holdings

View Profile
Address
One Azrieli Center
Tel Aviv TA 670110
Israel
Employees -
Website http://www.kitovpharma.com
Updated 07/08/2019
Kitov Pharma Ltd. is a development stage biopharmaceutical company, which engages in drug development. The firm offers Consensi and NT219. Consensi is intended to treat osteoarthritis pain and hyper tension simultaneously, while NT219 is a cancer therapy drug that delivers anti-tumor effects and increasing survical in various cancer models.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.